Navigation Links
Watson Launches Generic PROMETRIUM(R)
Date:3/2/2012

PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson has launched an authorized generic version of PROMETRIUM® (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM® Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They are also indicated for use in secondary amenorrhea.

Under the terms of the supply agreement, Abbott manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending January 31, 2012, PROMETRIUM® had sales of approximately $198 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. 

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

PROMETRIUM® is a registered trademark of Abbott Laboratories.(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )CONTACTS:  Investors: 

Patty Eisenhaur  

(862) 261-8141 

  

Media: 

Charlie Mayr 

(862) 261-8030 

 


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Present at the Barclays Capital 2012 Global Healthcare Conference
2. Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
3. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference
4. Watson to Present at the Citi 2012 Global Healthcare Conference
5. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
6. Watson Provides Update on Generic Lidoderm® Application
7. Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
8. Watson Confirms Court Stays Preliminary Injunction
9. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
10. Watson Acquires Ascent Pharmahealth for AU$375 Million
11. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Naveen Divakaruni, D.O., Advocate Medical Group in Aurora, IL, ... Dr. Divakaruni has achieved a high level of training and experience with the ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... Labyrinthe Labs ... support formula called Lefa . A soothing cream designed for fast-action relief of ... whole plant phytocannabinoids proven to soothe and support tired joints and muscles. , ...
(Date:5/17/2020)... Fla. (PRWEB) , ... May 17, 2020 , ... The ... anti-fungal, anti-tumor, and other beneficial properties is extracted from the Sea Cucumber in a ... the active ingredient. , You’ve heard it time and time again: “You get ...
Breaking Medicine Technology:
(Date:5/17/2020)... ... May 18, 2020 , ... R3 Stem Cell International is ... clinic. There are two program options for patients and their families, which are ... is unclear exactly what causes Autism Spectrum Disorder (ASD), there are several recent ...
(Date:5/16/2020)... , ... May 15, 2020 , ... On May 21, T1V will host a webinar ... Institute of USC, and a contributor to CBS news, as we address COVID-19 and the ... in most parts of the country since March, many questions are left unanswered as we ...
(Date:5/16/2020)... ... ... Dr. Tomasz Biernacki states that “If bunion and flat foot ... can keep the foot from being unable to fit into good supportive shoes in ... develop flat feet and bunion formation can have further knee pain, hip ...
(Date:5/15/2020)... ... 2020 , ... Collagen has taken the areas of beauty and anti-aging by ... to a 2020 Nutritional Outlook ‘Ingredients to Watch’ US forecast. Collagen ingredients have matured ... high molecular weight, low-impact products of the past to the clinically-studied, low-molecular weight hydrolysates ...
(Date:5/15/2020)... YORK (PRWEB) , ... May 15, 2020 , ... On ... come together for Home is Where the Heart Is, a benefit to support the ... rare genetic disorder that causes tumors to grow on nerves throughout the body and ...
Breaking Medicine News(10 mins):